PineStone Asset Management Inc. Sells 4,500 Shares of Medpace Holdings, Inc. $MEDP

PineStone Asset Management Inc. reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,700 shares of the company’s stock after selling 4,500 shares during the quarter. PineStone Asset Management Inc.’s holdings in Medpace were worth $13,873,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Quent Capital LLC purchased a new position in shares of Medpace during the third quarter valued at approximately $25,000. Optiver Holding B.V. purchased a new stake in shares of Medpace in the third quarter worth approximately $27,000. Quarry LP bought a new stake in shares of Medpace during the 3rd quarter worth approximately $35,000. Root Financial Partners LLC bought a new stake in shares of Medpace during the 3rd quarter worth approximately $38,000. Finally, Geneos Wealth Management Inc. boosted its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 20.30% of the company’s stock.

Medpace Trading Up 4.3%

Shares of NASDAQ:MEDP opened at $480.19 on Wednesday. The company has a market capitalization of $13.63 billion, a PE ratio of 31.38, a P/E/G ratio of 2.21 and a beta of 1.44. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92. The business’s fifty day simple moving average is $488.61 and its 200-day simple moving average is $537.50.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same period in the prior year, the business posted $3.67 EPS. The firm’s quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price for the company in a research report on Friday, February 13th. BMO Capital Markets restated a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their price target for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Finally, Mizuho set a $582.00 price objective on shares of Medpace in a report on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.